PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy

Yanping Li¹, Ting Zhang², Qinhui Liu¹ and Jinhan He¹,²*

¹Laboratory of Clinical Pharmacy and Adverse Drug Reaction, West China Hospital of Sichuan University, Chengdu, China, ²Department of Pharmacy, West China Hospital of Sichuan University, Chengdu, China

Polymeric micelles have attracted considerable attention for effective delivery of poorly water-soluble cancer drugs. Polyethylene glycol (PEG), which has been approved for human use by the US Food and Drug Administration, is the most commonly used hydrophilic component of polymeric micelles because it is biocompatible and biodegradable. One disadvantage of traditional polymeric micelles is that they include a large amount of inert carrier materials, which do not contribute to therapeutic activity but increase cost and toxicity risk. A better alternative may be "dual-functional" micellar carriers, in which the hydrophobic carrier material (conjugated to PEG) has intrinsic therapeutic activity that complements, or even synergizes with, the antitumor activity of the drug cargo. This review summarizes recent progress in the development of PEG-derivatized dual-functional nanomicelles and surveys the evidence of their feasibility and promise for cancer therapy.

Keywords: polyethylene glycol (PEG), dual-functional nanomicelles, cancer therapy, multidrug resistance, drug loading capacity, cancer immunochemotherapy

INTRODUCTION

Cancer has become the “first killer” that threatens human health (Siegel et al., 2017; Smith et al., 2017; Torre et al., 2017). Chemotherapy, one of the most important tools in clinical cancer treatment, inhibits growth of primary tumors and suppresses proliferation of metastatic tumor cells (Chabner and Roberts, 2005). Although many anticancer drugs have been approved, their clinical application is often compromised by poor water solubility, short circulation time, and serious systemic side effects (Shi et al., 2016; Youn and Bae, 2018). Nanomaterials have been widely used in cancer therapy (Wicki et al., 2015). Various nanocarriers, including nanoparticles (Geszke-Moritz and Moritz, 2016), liposomes (Cheng and Ji, 2019), micelles (Cagel et al., 2017), and dendrimers (Ray et al., 2018), have opened up new possibilities for sustained, controlled, and targeted cancer drug delivery, achieving higher effective drug concentrations at the tumor site with fewer off-target side effects. In particular, polymeric micelles have attracted attention as multifunctional drug delivery systems for poorly water-soluble agents (Zhang et al., 2014h; Biswas et al., 2016).

Polymeric micelles are self-assembling nanoparticles (5–200 nm) composed of amphiphilic polymers. The structure of polymeric micelles follows and exemplifies the similar structure of micelles proposed as per different micellar theories (Gothwal et al., 2016). It is composed of a "core," which is usually a hydrophobic section while the exterior, which is also known as “shell,” represents a hydrophilic block of the copolymer structure (Figure 1) (Mohamed et al., 2014; Zhang et al., 2014d). Polymeric micelles are easy to prepare, highly biocompatible, and quite efficient at encapsulating and delivering drugs in the body (Gong et al., 2012). Polymeric micelles can encapsulate...
water-insoluble agents in their hydrophobic core, improving bioavailability (Kedar et al., 2010; Tanbour et al., 2016). A hydrophilic shell of polyethylene glycol (PEG) can significantly prolong the circulation time of polymeric micelles in the blood (Suk et al., 2016). Polymeric micelle in the 10–100 nm range can pass through the leaky vasculature and passively accumulate in tumors via the enhanced permeability and retention effect (EPR) (Maeda et al., 2009; Fang et al., 2011; Maeda et al., 2013).

PEG, which has been approved by the US Food and Drug Administration (FDA) for use in human, is the most commonly used hydrophilic component of polymeric micelles (Molineux, 2002; Duncan, 2014; Qu et al., 2018). It is biodegradable and biocompatible because it does not form toxic metabolites, and it is commercially available in molecular weights ranging from 500 to 20,000 Da. Surface modification of PEG-based nanocarriers can reduce interactions with plasma proteins and nonspecific uptake by the reticuloendothelial system, prolonging time in systemic circulation (Bae and Kataoka, 2009; Wang et al., 2018a). The multifunctionality of PEG allows multiple drug or targeting molecules to be conjugated to the same polymer chain. Currently, several PEG-derivatized polymeric micelles carrying anti-cancer drugs are under clinical evaluation, including NK012, NK105, SP1049C, NK911, and Genexol-PM (Cabral and Kataoka, 2014; Mohamed et al., 2014; Deshmukh et al., 2017). In fact, regulatory authorities in South Korea have approved Genexol-PM for use against breast cancer.

In the “hydrophilic shell-hydrophobic core” architecture of polymeric micelles, the hydrophobic core provides a loading space for poorly water-soluble drugs (Zhang et al., 2014d). The polymers most commonly used to build the hydrophobic core are polypesters and polyamides, such as polycaprolactone, poly(lactic acid), poly(glycolic acid), and poly(ε-histidine) (Zhang and Zhuo, 2005; Zhang et al., 2014a; Zhang et al., 2014c). Most of these hydrophobic components are inert carrier materials without therapeutic activity. In other words, they add to the cost and toxicity risk of the drug delivery system, without contributing to therapeutic efficacy (Qu et al., 2017b). This has led researchers to explore nanocarriers that themselves have therapeutic effects.

Since Ringsdorf proposed the concept of “polymeric prodrug” in 1975, the utility of polymer-drug conjugates in clinical therapy has been well demonstrated (Hoste et al., 2004; Ringsdorf, 2010). Interestingly, hydrophobic drugs conjugated to hydrophilic polymers can self-assemble into micelles, which can then be loaded with another therapeutic molecule (Ulbrich and Subr, 2004; Greco and Vicent, 2008). Numerous bioactive hydrophobic agents have been conjugated to PEG to form so-called “dual-functional” micellar carriers, which have intrinsic antitumor activity and that deliver anti-tumor drug cargo (Mi et al., 2011; Huang et al., 2012; Chung et al., 2014; Zhang et al., 2014e). PEG-derivatized dual-functional micelles are typically prepared with one of two types of hydrophobic material (Qu et al., 2017b): anti-cancer natural products not yet used clinically, such as vitamin E succinate, (−)-epigallocatechin-3-gallate, embelin, and S-trans,farnesylthiosalicylic acid, or anti-cancer molecules already established in the clinic, such as camptothecin (CPT), doxorubicin (DOX), paclitaxel (PTX), and docetaxel (Figure 2).

In this review, we summarize recent progress in PEG-derivatized dual-functional micellar carriers and their application in cancer therapy. Strategies to improve carrier–drug interactions are discussed because two challenges in the development of polymeric micelles are their drug-loading capacity and stability. Recent developments in exploiting dual-functional carriers for therapies combining immuno- and chemotherapy are also surveyed.

**PEG-DERIVATIZED DUAL-FUNCTIONAL MICELLES WITH INTRINSIC ANTI-CANCER ACTIVITY**

**PEG-Derivatized Vitamin E**

Vitamin E succinate (D-α-tocopherol, α-TOS) is a derivative of vitamin E that shows activity against various types of cancers, including breast, lung, and prostate (Malafa and Neitzel, 2000; Malafa et al., 2002; Kline et al., 2004). α-TOS can selectively kill tumor cells without affecting normal cells by inhibiting angiogenesis, suppressing activation of NF-κB, and generating reactive oxygen species (Dong et al., 2007; Jin et al., 2014). It can also enhance the cytotoxicity of PTX and DOX (Kayani et al., 2010), and it can inhibit P-glycoprotein (P-gp) to overcome multidrug resistance (MDR) (Constantinides et al., 2006).

The poor water solubility of α-TOS has limited its use in vivo, leading researchers to explore possibilities with D-α-tocopheryl PEG succinate (vitamin E TPGS, or simply TPGS), which is a water-soluble derivative of α-TOS generated by esterification with PEG (Yook et al., 2005). TPGS acts as a nonionic surfactant: it exhibits amphipathic properties and can form micelles in aqueous media at a critical micelle concentration (CMC) of 0.2 mg/ml. It has been investigated as an absorption enhancer, emulsifier, solubilizer, additive and permeation enhancer, and stabilizer (Zhang et al., 2012; Guo et al., 2013). TPGS also inhibits P-gp-mediated drug efflux by inhibiting the ATPase of P-gp and mitochondrial respiratory complex II (Dong et al., 2008; Collinot et al., 2010). The relatively high CMC of TPGS and its relatively
short PEG chains mean that TPGS-based micelles usually leave the circulation quickly and accumulate in the liver and spleen (Tan et al., 2017; Yang et al., 2018a). Therefore, TPGS is usually mixed with other lipids or copolymers to form micelles. Research groups have taken different approaches to improving the properties of TPGS as a micelle carrier (Figure 3). Conjugating tocopheryl succinate to PEG 2000 leads to TPGS\(_{2K}\), which has a much lower CMC than TPGS, allowing formation of stable drug-loaded micelles without addition of other lipids or polymers. For example, one group developed TPGS\(_{2K}\) polymer-based micelles with a CMC of only 0.0219 mg/ml (Mi et al., 2011). Docetaxel was successfully loaded in TPGS\(_{2K}\) micelles to form a uniform sphere with an average diameter of 15 nm. In vitro antitumor results showed that docetaxel-loaded TPGS2K micelles dramatically decreased the IC\(_{50}\) values of MCF-7 cells (0.526 g/ml) compared with that of the free docetaxel (103.4 g/ml), indicating a synergistic therapeutic effect between TPGS\(_{2K}\) and docetaxel. Another group conjugated PEG to two vitamin E molecules to form star-shaped copolymer PLV\(_{2K}\) micelles with a CMC of only 1.14 μg/ml (Wang et al., 2012). DOX was encapsulated into the hydrophobic core of PLV\(_{2K}\) with encapsulation efficiency as high as 94.5%, and the drug-loaded micelles inhibited growth of 4T1 breast cancer tumors in mice more effectively than free DOX or DOX-loaded in TPGS.

Screening two PEG lengths (PEG\(_{2K}\) or PEG\(_{5K}\)) and two molar ratios of PEG to vitamin E (1:1 or 1:2) identified PEG\(_{5K}\)-VE\(_2\) micelles comprising one PEG\(_{5K}\) and two vitamin E molecules as having the lowest CMC and most efficient PTX loading (Lu et al., 2013a; Lu et al., 2014c). Loading PTX into PEG\(_{5K}\)-VE\(_2\) inhibited tumor growth in mice significantly better than loading it into PEG\(_{5K}\)-VE or PEG\(_{5K}\)-VE\(_2\), or than using Taxol. Our group has analyzed how the molar ratio of PEG to vitamin E affects the stability, drug loading capacity, and tumor targeting efficiency of TPGS-based micelles in vitro and in vivo (Li et al., 2016a; Li et al., 2016b). PAMV\(_{6}\), which is formulated with a 1:6 molar ratio of PEG to vitamin E and shows a wheat-like structure, showed the lowest CMC, greatest stability in serum, and highest tumor distribution and retention. Moreover, PAMV\(_{6}\) inhibits P-gp efflux activity, not by affecting P-gp expression, but by decreasing mitochondrial membrane potential and intracellular levels of ATP (Li et al., 2016a). As a result, pirarubicin-loaded PAMV\(_{6}\) micelles inhibited the growth of MCF-7/ADR xenograft tumors in mice significantly better than free pirarubicin, with significantly less systemic and organ-specific toxicity.

**PEG-Derivatized EGCG**

The most abundant catechin in green tea, (−)-epigallocatechin-3-gallate (EGCG), shows activity against cancer, diabetes, neurodegenerative disease, stroke, obesity, and other disorders (Chakrawarti et al., 2016; Song et al., 2017). EGCG can inhibit tumor growth and metastasis by interrupting key signaling and
metabolic pathways that support cancer cell survival without damaging normal cells (Shankar et al., 2007; Wang et al., 2018b). For example, EGCG can down-regulate PEA15 expression and enhance TRAIL-mediated apoptosis in tumor cells (Siegelin et al., 2008; Le et al., 2018). EGCG interacts with the estrogen receptor to inhibit estrogen-induced proliferation of breast cancer cells and sensitize hormone-responsive tumors to drugs such as tamoxifen that target steroid receptors (Farabegoli et al., 2007; Tu et al., 2011).

Despite its clear therapeutic effects, EGCG remains far from clinical use, in large part because of its low stability and bioavailability. The several hydroxyl groups in EGCG make it highly hydrophilic, which resulted in short circulation half-time. One group developed a micellar nanocomplex (MNC) comprising two EGCG derivatives that bind to proteins in a spatially ordered structure (Chung et al., 2014). MNCs self-assemble in two steps: first, oligomerized EGCG (OEGCG) complexes with the humanized monoclonal therapeutic antibody Herceptin (trastuzumab) to form a core; second, PEG-EGCG assembles as a shell around this core. The resulting MNC is monodisperse and spherical, with a mean diameter of about 90 nm and good stability in serum at 37°C for 15 days. Both in vitro and in vivo therapeutic studies showed that Herceptin-MNC had superior anti-tumor effects to free Herceptin. While Herceptin on its own shows anti-tumor activity, it synergizes with the EGCG within MNC to cause even greater inhibition, with a combination index of 0.93. Similarly, replacing Herceptin with interferon α-2a generates an MNC that inhibits the growth of HAK-1B human liver cancer cells more than free interferon α-2a, with a combination index of 0.46.

EGCG inhibits P-gp (Jodoin et al., 2002) and can sensitize drug-resistant tumor cells to DOX and increase DOX accumulation in MDR cells (Liang et al., 2010; Song et al., 2017). Thus, combination therapy with EGCG and DOX may simultaneously overcome DOX-induced cardiotoxicity and MDR. Special methods are needed to co-load DOX and EGCG into micelles, since DOX is hydrophobic while EGCG is hydrophilic and unstable. To achieve such co-loading, a novel green tea catechin-based
polyion complex was developed in which DOX and EGCG were co-loaded \textit{via} electrostatic interactions as well as interactions between EGCG and poly(ethylene glycol)-block-poly(lysine-co-lysine-phenylboronic acid) (Cheng et al., 2016). This allowed DOX to be loaded into the micelles with a drug loading capacity of 12.4\% and drug loading efficiency of 55\%. The ability of EGCG to scavenge oxygen free radicals and inhibit P-gp means that these vesicles may simultaneously overcome DOX-induced cardiotoxicity and MDR (Mei et al., 2004; Yao et al., 2017).

**PEG-Derivatized Embelin**

Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone), a major active constituent of the \textit{Embelia ribes} Burn plant, possesses analgesic, anti-diabetic, anti-inflammatory, and hepatoprotective activities (Chitra et al., 1994; Naik et al., 2013; Peng et al., 2014). It also inhibits growth of breast, colon, prostate, and pancreatic tumors \textit{via} several different mechanisms. In most cases, the compound induces intrinsic or extrinsic apoptotic cell death and modulates signaling pathways involving NF-κB, p53, PI3K/AKT, and STAT3 (Heo et al., 2011; Kim et al., 2013; Ko et al., 2018). Interestingly, \textit{in silico} screening predicts that embelin inhibits the X-linked inhibitor of apoptosis protein (XIAP), which is over-expressed in a variety of cancers, especially drug-resistant ones (Nikolovska-Coleska et al., 2004; Hussain et al., 2017). Several synthetic peptide inhibitors of XIAP have been reported, and some are in clinical trials, but embelin would be the only naturally occurring non-peptide XIAP inhibitor reported so far.

Embelin is poorly water-soluble and has limited oral bioavailability. Modifying it with PEG can significantly increase its water solubility, and the resulting PEG-embelin conjugates can self-assemble to form micelles and efficiently encapsulate hydrophobic drugs such as PTX and DOX (Huang et al., 2012). Screening two PEG lengths (PEG$_{1.5k}$ or PEG$_{3k}$) and two molar ratios of PEG to EB (1:1 or 1:2) showed that PEG$_{3k}$-EB$_2$, in which two embelin molecules were linked \textit{via} aspartic acid to one PEG$_{3k}$, showed the lowest CMC and highest PTX loading efficiency (Lu et al., 2013b). When these micelles were loaded with PTX, the embelin and PTX synergized to inhibit cancer cell growth \textit{in vitro} even when PTX were present at nanomolar concentrations. The same micelles also inhibited growth of 4T1 breast cancer tumors and PC-3 prostate cancer tumors in mice better than Taxol, with minimal toxicity.

To improve the targeting ability of PEG$_{3k}$-EB$_2$ micelles, folic acid (FA) was coupled to the surface and the resulting FA-PEG$_{3k}$-EB$_2$ were able to readily self-assemble to form nanomicelles with a particle diameter around 20 nm (Lu et al., 2014b). FA-PEG$_{3k}$-EB$_2$ significantly facilitated the intracellular uptake of DOX over free DOX and Doxil in breast cancer cells 4T1.2, and drug-resistant cells NCI/ADR-RES. Consistent with better tumor targeting, the FA-decorated micelles inhibited the growth of 4T1.2 metastatic breast cancer tumors in mice significantly more than free DOX, Doxil or the micelles without FA, and with lower toxicity.

PEG-embelin micelles, in addition to enhancing the antitumor efficacy of PTX or DOX, can also inhibit P-gp ATPase activity analogously to TPGS and thereby can sensitize drug-resistant NCI/ADR-RES cells to DOX (Lu et al., 2013b; Lu et al., 2014b). Further studies should clarify whether PEG-embelin micelles act as a non-competitive or competitive inhibitor of the P-gp ATPase.

**PEG-Derivatized Farnesylthiosalicylic Acid**

\textit{S-trans, trans}-farnesylthiosalicylic acid (FTS) is a synthetic farnesylcysteine mimic with strong potential to be an effective cancer drug (Kloog and Cox, 2000; Erlich et al., 2006). As a first-in-class Ras inhibitor, it is in phase II clinical trials to treat pancreatic cancer and lung adenocarcinoma (Riely et al., 2011; Laheru et al., 2012). FTS may also be effective against other cancers in which mutated Ras proteins are constitutively active (Simanshu et al., 2017), and it so far has shown minimal side effects (Gana-Weisz et al., 2002). FTS can also suppress cancer cell growth and proliferation by inhibiting mTOR, especially in endocrine-resistant breast cancer (McMahon et al., 2005).

Its long hydrophobic chains make FTS poorly water-soluble, so it is usually PEGylated when forming micelles (Figure 4). For example, conjugation two FTS to PEG \textit{via} a labile ester linkage readily forms PEG$_{3k}$-FTS$_2$(L) micelles in aqueous solution, which inhibit tumor growth in mice to a similar extent as free FTS (Zhang et al., 2013). Loading these micelles with PTX or curcumin led to synergy between these compounds and the FTS, such that micelle cytotoxicity was higher than with PTX or curcumin on their own (Zhang et al., 2013; Chen et al., 2014). Breaking the linkage between PEG and FTS appears to be critical for its anti-tumor activity: replacing the ester linkage with a more stable amide linkage resulted in significantly lower cytotoxicity (Zhang et al., 2013). It is likely that FTS is much more readily released from PEG$_{3k}$-FTS$_2$(L) than PEG$_{3k}$-FTS$_2$(S) with a stable amide linkage. \textit{In vitro}, PEG$_{3k}$-FTS$_2$(L) alone was more much more active than PEG$_{3k}$-FTS$_2$(S) in antitumor activity in both 4T1.2 and HCT-116 cell lines. \textit{In vivo}, PTX formulated in PEG$_{3k}$-FTS$_2$(L) showed antitumor activity that is more potent that than of Taxol or PTX/PEG$_{3k}$-FTS$_2$(S). Glutathione is present in tumors at much higher concentrations than in extracellular fluids (Saito et al., 2003; Zhang et al., 2018b), so coupling the FTS to PEG \textit{via} a disulfide linkage can lead to greater release of FTS inside tumor cells and therefore to greater cytotoxicity than either Taxol or PTX (Zhang et al., 2014g).

Screening of two weights of PEG (PEG$_{3k}$ vs. PEG$_{5k}$) and two molar ratios PEG: FTS (1:2 or 1:4) identified PEG$_{3k}$-FTS$_2$ as the stabllest and most cytotoxic micelles against 4T1.2 breast cancer tumors in mice (Zhang et al., 2014e). Adding the 9-fluorenylmethoxycarbonyl (Fmoc) moiety to these micelles significantly improved the loading capacity of PTX and DOX as well as efficacy against breast and prostate cancer tumors in mice (Zhang et al., 2014f). Incorporating a disulfide linkage into Fmoc-modified PEG$_{3k}$-FTS$_2$ micelles reduced the CMC to 0.02 μM, which was 10-fold lower than the CMC of micelles without either the Fmoc moiety or disulfide linkage (Xu et al., 2017). It also increased accumulation inside prostate cancer tumors in mice by two- to three-fold. The disulfide linkage also increased the cytotoxicity \textit{in vitro} and \textit{in vivo} when Fmoc-modified micelles were loaded with PTX. These studies indicate that PEG-FTS is

Frontiers in Pharmacology | www.frontiersin.org 5 July 2019 | Volume 10 | Article 808
an effective dual-functional carrier that can synergize with co-delivered anti-cancer agents.

**PEG-Derivatized Anticancer Drugs**

Most small-molecule anti-cancer drugs are hydrophobic. Their water solubility and circulation time can be improved by creating PEGylated prodrug copolymers that self-assemble into micelles. These PEG-drug conjugates can also be used to carry additional chemotherapeutic agents (Table 1). Below, we discuss only PEGylated prodrug complexes to which additional drugs are added. PEGylated drug complexes without further drug addiction have been reviewed elsewhere.

The natural cytotoxic quinoline alkaloid CPT inhibits DNA topoisomerase I, making it effective against a wide spectrum of cancers (Gromova et al., 1990; Pizzolato and Saltz, 2003; Zunino and Pratesi, 2004). However, the clinical use of CPT is limited by its extremely hydrophobicity and low stability in vivo (Koo et al., 2005; Botella and Rivero-Buceta, 2017). A CPT-PEG-CPT prodrug has been prepared by conjugating two molecules of CPT to the ends of PEG via degradable ester linkage (Dong et al., 2012). This complex, which can accommodate CPT up to 41%, self-assembled into micelles with a diameter of 50 nm. DOX was loaded into the micelles with high capacity, and the complex showed greater cytotoxicity than free DOX. The increased cytotoxicity might be induced by the combined effect of both DOX and CPT. Further, they introduced redox-responsive disulfide linkers and prepared a micellar system (CPT-SS-PEG-CPT) to achieve an aim of rapidly releasing the native CPT in tumor-relevant reductive conditions (Li et al., 2011). An amphiphilic prodrug of CPT has been prepared by polymerizing γ-CPT glutamate N-carboxyanhydride with mPEG via pH-sensitive boronate ester bonds (Gao et al., 2018). The resulting prodrug self-assembled into micelles, simultaneously encapsulating DOX. These micelles showed sustained drug release during 48 h, which increased when pH was reduced from 7.4 to 6.0. This approach may promote uptake of the micelles and drug release specifically in the acidic tumor microenvironment.

PTX, isolated from *Taxus brevifolia*, is one of the most effective chemotherapeutic drugs against ovarian, lung, breast,
and other cancers (Wani et al., 1971; Blair and Deeks, 2015; Bourgeois-Daigneault et al., 2016). Its aqueous solubility is only about 0.3 mg/ml, so it is solubilized with polyoxyethylenated castor oil (Cremophor EL) in the commercial formulation of PTX, called Taxol. Cremophor EL can cause serious hypersensitivities, neurotoxicity, and nephrotoxicity, which severely limit the success of PTX chemotherapy (Singla et al., 2002; Nehate et al., 2014). To avoid these problems, mPEG5000 and PTX have been conjugated via succinic anhydride as linker, giving a water-soluble PTX prodrug (Greenwald et al., 1996). Although this prodrug appears to have negligible anti-tumor activity because PTX release is too low (Liang et al., 2012), the prodrug can complex with free PTX to form spherical particles of 100–200 nm (Lu et al., 2014a). These particles inhibited the growth of MCF-7 tumors in mice significantly better than Taxol, and with less toxicity. To allow breakage of the PEG-PTX bond under certain conditions, PEG and PTX have been conjugated using an acetal linker that cleaves preferentially when exposed to endosomal pH (Huang et al., 2018). This prodrug self-assembles into micelles and can encapsulate free PTX into the hydrophobic core, such that the total PTX concentration in the micelles reaches a capacity of 60.3%. These PTX-loaded micelles inhibited HeLa and MDA-MB-231 cells more than free PTX.

**PEG-DERIVATIZED DUAL-FUNCTIONAL MICELLES FOR IMMUNOCHEMOTHERAPY**

Accumulation evidence suggests that chemotherapy-induced immune responses contribute to the overall anti-tumor effects of chemotherapy (Vanneman and Dranoff, 2012; Bracci et al., 2014; Kumar et al., 2017). However, cancer treatment also up-regulates various negative feedback mechanisms that limit the effectiveness of chemotherapy-elicted immune responses as well as other immunotherapies (Curran et al., 2010; Jiang et al., 2019). For example, indoleamine 2,3-dioxygenase (IDO) is a negative feedback protein that helps tumors evade the immune system, grow, and metastasize (Soliman et al., 2010; Ricciuti et al., 2019; Zhu et al., 2019); IDO causes immunosuppressive effects by inhibiting T cell differentiation and proliferation (Uyttenhove et al., 2003; Zamanakou et al., 2007). Reversing these negative feedback mechanisms may have anti-tumor effects. NLG919, a highly selective IDO inhibitor with a median effect concentration of 75 nM, promotes growth of T and natural killer cells, increases interferon production, and reduces conversion to a regulatory T cell phenotype (Mautino et al., 2013; Li et al., 2014; Meng et al., 2017). NLG919 is poorly water soluble, and it cannot be simply co-delivered as a mixture with drugs because of differences in physico-chemical and pharmacokinetic profiles (Liu et al., 2010).

NLG919 has been conjugated with PEG in a dual-functional, immunostimulatory micelle in which the Fmoc group was introduced to improve drug loading capacity and formulation stability (Chen et al., 2016). The resulted PEG<sub>2k</sub>-Fmoc-NLG micelles self-assembled in aqueous solutions to form particles of about 90 nm with a CMC of 0.737 mM. It's found that PEG<sub>2k</sub>-Fmoc-NLG with a relatively labile ester linkage well retained the pharmacological activity of NLG919 and significantly enhanced T-cell immune responses. The micelles could also be loaded with several common drugs: PTX, docetaxel, DOX, gefitinib, imatinib, and curcumin. PTX-loaded PEG<sub>2k</sub>-Fmoc-NLG micelles were delivered intravenously into mice bearing breast cancer tumors or melanomas, and they showed significantly greater anti-tumor response than free PTX or the empty micelles without PTX.

These PTX-loaded micelles also enhanced anti-tumor immune responses, yet they triggered the counter-productive accumulation of myeloid-derived suppressor cells (MDSCs), which maintain a highly immunosuppressive tumor microenvironment (Pastaki Khoshbin et al., 2019; Safari et al., 2019; Groth et al., 2019). MDSCs can induce immunosuppression by up-regulating inducible nitric oxide synthase and arginase I, thereby inhibiting T-cell function (Meirow et al., 2015). MDSCs can enhance tumor

### TABLE 1 | Polyethylene glycol (PEG)-derivatized anticancer drug as dual-functional micellar carrier.

| Self-assembled prodrugs | Hydrophobic drug | Co-loaded drug | In vitro/in vivo experimental model | References |
|-------------------------|------------------|----------------|-----------------------------------|------------|
| CPT-SS-PEG-SS-CPT       | Camptothecin     | Camptothecin   | HepG2 human hepatoma cell model   | [Li et al., 2011] |
| CPT-PEG-CPT             | Camptothecin     | Doxorubicin    | Human cervical cancer Hela cells  | [Dong et al., 2012] |
| mPEG-BC-PGluCPT         | Camptothecin     | Doxorubicin    | HepG2 and HL-7702 cells           | [Gao et al., 2018] |
| P(CTMA-co-PEMA)         | Camptothecin     | Glucose oxidase| AS49 tumors                       | [Li et al., 2017] |
| PEG-BiPTC             | Camptothecin     | β-lapachone    | Mouse breast cancer 4T1 cell line and 4T1 tumor-bearing mice | [Yin et al., 2019] |
| PEG-PTX                 | Paclitaxel       | Paclitaxel     | MCF-7 cells and mouse xenograft tumor model bearing MCF-7 cells | [Lu et al., 2014a] |
| PEG-acetal-PTX          | Paclitaxel       | Paclitaxel     | HeLa and MDA-MB-231 cells         | [Huang et al., 2018] |
| mPEG-b-DOX              | Doxorubicin      | Verapamil      | MCF-7/ADR cell line               | [Zhao et al., 2015] |
| PEG-CH = N-DOX          | Doxorubicin      | 7-ethyl-10-hydroxyl-camptothecin | MCF-7 cells and mouse xenograft tumor model bearing MCF-7 cells | [Sun et al., 2018b] |
| PEG-DTX                 | Docetaxel        | Docetaxel      | H460 human non-small cell lung, SKOV-3 human ovarian and MCF-7 human breast cancer cells | [Lu et al., 2008] |
| PEG-CM#APTES-COF-1      | Curcumin         | Doxorubicin    | HeLa cells and HeLa cell xenograft tumor mice model | [Zhang et al., 2018a] |
| PEG-Fmoc-GA             | Glycyrrhizic acid| Doxorubicin    | HepG2 cells human liver cancer xenograft model | [Yang et al., 2018b] |
cell proliferation, facilitate tumor metastasis and angiogenesis, and promote drug resistance (Draghiciu et al., 2015; Gabriilovich, 2017). Increased numbers of tumor-infiltrating MDSCs often correlate with high tumor burden and metastasis, contributing to poor prognosis (Nagaraj and Gabriilovich, 2008; Malek et al., 2016). To avoid stimulating MDSCs, a dual-functional carrier of PEG linked to NLG919 via an Fmoc moiety was loaded with both PTX and sunitinib (Chen et al., 2018), an FDA-approved tyrosine kinase inhibitor for the treatment of various cancers. Sunitinib reduces the level and activity of MDSCs and Treg cells systemically and in the tumor microenvironment (van Hooren et al., 2016; Motzer et al., 2017). These micelles then deliver three anti-tumor components to the cancer: PTX and sunitinib lead to synergistic killing of tumor cells as well as the induction of anti-tumor immune responses following the release and presentation of tumor antigens, sunitinib inhibits cytokines needed to recruit MDSCs, and NLG919 is released quite slowly to inhibit IDO and thereby sustain an immune-active tumor microenvironment.

In other studies, the dual-functional carrier of PEG-linked to NLG919 via an Fmoc moiety was loaded with DOX for immunochemotherapy against lymphoma (Zhai et al., 2017). The DOX-loaded micelles were small (<120 nm), showed sustained drug release, and triggered significantly large numbers of total CD4+/CD8+ T cells and functional CD4+/CD8+ T cells in mice with lymphoma than the same micelles without DOX. These micelles, whether loaded with DOX or not, reduced the recruitment of granulocytic MDSC and monocyctic MDSCs to tumor tissues. This contrasts with the observation that the same micelles, when loaded with PTX, triggered the counter-productive accumulation of MDSCs (Chen et al., 2018). These differences may reflect the different abilities of DOX and PTX to modulate the immune system. More studies are needed to better understand the impact of different immunochemotherapies on the tumor microenvironment and overall anti-tumor effects.

PEG-DERIVATIZED DUAL-FUNCTIONAL MICELLES WITH IMPROVED DRUG LOADING CAPACITY

Dual-functional micelles not only exert intrinsic therapeutic effects, but also deliver other drugs to tumor sites. Most of these micelles load drugs via hydrophobic interaction, hydrogen bonding, and π-π stacking between the encapsulated drug and the hydrophobic components of the micelle (Lu et al., 2013a; Mohamed et al., 2014). This means that one way to improve drug loading capacity is to increase the density of the hydrophobic component. Conjugating PEG to multiple vitamin E molecules rather than one molecule improved drug loading capacity (Wang et al., 2012), and increasing the number of vitamin E, embelin, or FTS molecules conjugated to one PEG molecule increased drug loading capacity (Lu et al., 2013b; Lu et al., 2014c; Zhang et al., 2014e). We found that conjugating PEG to six vitamin E molecules (PAMV<sub>6</sub>) gave the highest drug loading capacity (Li et al., 2016b). The wheat-like structure of the hydrophobic chains of PAMV<sub>6</sub> likely creates a binding pocket that enhances the interaction between carrier and loaded drug. However, increasing the number of conjugated vitamin E molecules to 10 (PAMV<sub>10</sub>) gave heterogeneous micelles, presumably because the balance between hydrophilic and hydrophobic chains was destroyed. These results suggest that increasing the density of the hydrophobic component can increase drug loading capacity only to a certain extent.

While the dual-functional micelles discussed so far in this review are effective in formulating drugs that are strongly hydrophobic, they are less effective at formulating moderately hydrophobic drugs. This can be improved by introducing hydrotropic motifs into the hydrophobic domain of polymeric micelles, which improves drug loading capacity and micelle stability (Cho et al., 2004; Huh et al., 2005). In fact, covalent coupling of the moderately hydrophobic DOX into the hydrophobic domain of polymeric micelles improves the loading capacity of free DOX (Yoo and Park, 2004b; Yoo and Park, 2004a).

Another way to improve drug-loading capacity and formulation stability is to incorporate a surfactant at the interface between carrier and drug (Gao et al., 2013). The Fmoc moiety, a functional group routinely used to protect amino acids, is one of the most potent drug-interacting motifs (Table 2). Fmoc-based micelles can effectively encapsulate six drugs with diverse structures: probucol, nicosamide, progesterone, cyclosporin A, nifedipine, and griseofulvin (Gao et al., 2013; Zhang et al., 2014b). Hydrophobic interactions and π-π stacking may contribute to drug-Fmoc interactions. Consistent with this idea, introduction of the Fmoc domain into PEG-derivatized vitamin E (Zhang et al., 2014f; Xu et al., 2017) and FTS carriers (Zhang et al., 2014i; Lu et al., 2015) improves their drug-loading capacity, probably because the Fmoc can engage in stacking interactions with the interfacial aromatic ring of vitamin E and FTS. A PEG-derivatized ibuprofen conjugate (PEG<sub>2K</sub>-Fibu) consisting of a hydrophilic PEG segment, Fmoc motif, and hydrophobic ibuprofen domain readily formed stable micelles with PTX in the nanosize range (~100 nm) to a relatively high loading capacity of 67% (Zhao et al., 2016). In vitro cytotoxicity showed that PTX formulated in PEG<sub>2K</sub>-Fibu micelles was comparable to Taxol in inhibiting the proliferation of tumor cells. The lack of synergy between the ibuprofen-based carrier and PTX is likely due to the very low concentrations of carriers used in the cytotoxicity study. In vivo, PTX-loaded PEG<sub>2K</sub>-Fibu micelles showed a much more pronounced therapeutic efficacy compared with Taxol formulation. The improved antitumor activity of PTX-loaded PEG<sub>2K</sub>-Fibu micelles is likely attributed to the enhanced delivery of PTX to the tumors and the potential synergy between the micellar carrier and PTX.

CHALLENGES AND FUTURE CONSIDERATIONS OF DUAL-FUNCTIONAL MICELLAR CARRIER

A large number of preclinical studies on dual-functional micelles have been published, which showed great promise to be an
TABLE 2 | Fmoc-based PEG-derivatized dual-functional micellar systems.

| PEG-derivatized micellar carriers | Hydrophobic segment | Co-loaded drug | Drug loading capacity | Drug loading efficiency | References |
|----------------------------------|---------------------|----------------|----------------------|------------------------|------------|
| PEG<sub>5K</sub>-Fmoc-VE<sub>2</sub> | Vitamin E | Doxorubicin | 39.9% | 79.5% | (Lu et al., 2014c) |
| PEG<sub>5K</sub>-Fmoc-VE<sub>2</sub> | Vitamin E | Paclitaxel | 20.8% | 80.7% | (Zhang et al., 2014d) |
| PEG<sub>5K</sub>-Fmoc-VE<sub>2</sub> | Vitamin E | Camptothecin | 9.2% | 70.5% | (Lu et al., 2015) |
| PEG<sub>5K</sub>-Fmoc-FTS<sub>2</sub> | S-trans,transfarnesylthioacrylic acid | Paclitaxel | 12.1% | 55.4% | (Zhang et al., 2014a) |
| PEG<sub>5K</sub>-Fmoc-S-S-FTS<sub>2</sub> | S-trans,transfarnesylthioacrylic acid | Doxorubicin | 32.8% | 69.7% | (Lu et al., 2014c) |
| PEG<sub>5K</sub>-Fmoc-GA | Glyceric acid | Paclitaxel | 34.0% | 53.5% | (Xu et al., 2017) |
| PEG<sub>5K</sub>-Fmoc-NLG | NLG919 | Doxorubicin | 7.3% | 93.2% | (Yang et al., 2018b) |
| PEG<sub>5K</sub>-Fmoc-NLG | NLG919 | Paclitaxel | 24.7% | – | (Chen et al., 2016) |
| PEG<sub>5K</sub>-Fmoc-NLG | NLG919 | Sunitinib | 5.6% | 98.3% | (Chen et al., 2018) |
| PEG<sub>5K</sub>-Fmoc-NLG | NLG919 | Doxorubicin | 15.6% | 93.6% | (Zhai et al., 2017) |
| PEG<sub>5K</sub>-Fmoc-ibu | Ibufrofen | Paclitaxel | 67.3% | 88.4% | (Zhao et al., 2016) |

**effective nanomedicine platform for drug delivery and cancer therapy.** However, the clinical translation and desired therapeutic effects of dual-functional micelles are still far from satisfactory (Cabral and Kataoka, 2014). Micellar system share the limitations inherent to other nanodelivery system which mainly rely on the passive targeting of tumors based on the EPR effect (Fang et al., 2011). Poor tumor penetration due to high interstitial pressure and inefficient tumor cell uptake as well as off target liver and spleen accumulations have been repeatedly reported with the use of micelles (Taurin et al., 2012). The targeting effect in human sometimes is not as pronounced as that obtained in the simple cell or animal models due to the complexity of the human body. To this end, ligand-installed polymeric micelles have the potential for overcoming such biological barriers by taking advantage of receptor-mediated active target mechanisms (Deshayes et al., 2013). The end-group of the PEG segment can be readily modified with ligands capable of recognition of cell-specific surface receptors, providing cellular selectivity and superior intracellular delivery to dual-functional polymeric micelles. The effect of various ligands, including peptides, antibody fragments, and small molecules, installed on nanocarriers, has been confirmed to improve their targeting efficiency (Allen, 2002; Bae et al., 2005). For example, cyclic-RGD (cRGD) peptides have been recognized as specific ligands for integrin αvβ3 which is overexpressed in neovasculature and tumor cells (Kulhari et al., 2015; Li et al., 2019). cRGD-modified polymeric micelles loaded with DACHPtl not only enhanced the cellular uptake of micelles by cancer cells, but also achieved efficient drug delivery in a mouse model of glioblastoma (Miura et al., 2013). Even though glioblastoma is notorious for its poor permeability due to the presence of the blood–brain tumor barrier, these cRGD-installed micelles rapidly penetrated and accumulated within tumor tissues.

Besides, the premature drug release in the bloodstream and inadequate drug release in the tumor may also account for the inferior therapeutic effects in human patients. Most of toxicities reported in clinical trials results from the micelle releasing the drug in the blood, causing toxic side effects similar to the free drug and thereby deviate from tumor targeting (Miller et al., 2013). Ideally, the drug is retained in the polymeric micelles during circulation but is released after accumulation in the tumor interstitium. The design of stimuli-responsive nanomicellar carriers is a very effective way to achieve tumor-targeted drug delivery and adequate release (Zhou et al., 2018a). Numerous stimuli-responsive dual-functional nanomicelles have been developed to deliver anticancer drug in response to a variety of extra/intracellular stimuli or external triggers, including pH, redox potential, enzymes, temperature, light, ultrasound, and magnetic field (Kalhapure and Renukunta, 2018). It is reported that the microenvironment of most solid tumors is intrinsically acidic (pH 6.5–7.2), while the pH value in the blood and normal tissue is about 7.4. An even lower acidic pH is found in endosomes and lysosomes (pH 4.5–6.5) (Qu et al., 2017a; Liang et al., 2019). Accordingly, the difference in pH has been widely exploited to achieve tumor site- or organelle-specific activation of pH-responsive nanomicelles. Yang et al. developed a novel multifunctional pH-sensitive nanomicelle based on luteinizing hormone-releasing hormone (LHRH)-PEG-PHis-DOX/DOX-trans-activating transcriptional activator (TAT) acid-sensitive micelle, which could dissociate and release DOX-TAT when responding to the tumor extracellular pH (Yang et al., 2015). Such systems could efficiently go across the cell membrane and reach the cytosol of the multidrug-resistant cancer cells, resulting in the remarkable antitumor efficacy and negligible systemic toxicity.

In addition, PEG is believed to provide a steric barrier around the nanocarriers, and thus prolonging their blood circulation time. However, there was an unexpected pharmacokinetic alteration brought about with a second dose of PEGylated nanoparticles, the so-called accelerated blood clearance (ABC) phenomenon (Ishida and Kiwada, 2008). With this phenomenon, a second dose of PEG-derivatized nanomicelles, PEGylated liposomes, or PEG-containing microemulsions is rapidly cleared from circulation when administered within a certain time interval from injection of the first dose due to an enhanced accumulation in the liver (Abu Lila et al., 2013). Many attempts have focused on the use of other polymers, such as chitosan and hyaluronic acid, to replace PEG modification and to avoid the occurrence of the ABC phenomenon (Dong et al., 2016). Moreover, polyetherimide-based dual-functional carrier is an alternative strategy for the delivery of charged macromolecules, such as antisense oligonucleotides, plasmid DNA, and siRNA/
miRNA (Zhou et al., 2018b). David Oupicky’s group developed many polycationic CXCR4 antagonist based dual-functional nanomicellar carriers that can simultaneously deliver siRNA and inhibit CXCR4 to achieve combination anticancer therapy (Li et al., 2012; Zhou et al., 2018b). Such dual-function delivery vectors could enhance antitumoral efficacy of a variety of cancer gene therapy methods (Li and Oupicky, 2014; Sun et al., 2018a).

CONCLUSIONS

Dual-functional nanomicelles have emerged as a versatile and powerful platform for cancer therapy. They can self-assemble and efficiently encapsulate chemotherapeutic agents such as PTX and DOX into their hydrophobic core. They exert anti-tumor effects by virtue of the encapsulated drug as well as the intrinsic anti-cancer activity of carrier materials in the micelles. As a result, these micelle systems can enhance the efficacy of anti-tumor drugs while reducing their systemic toxicity; in fact, the carrier materials and drug cargo can synergize to increase efficacy.

REFERENCES

Abu Lila, A. S., Kiwada, H., and Ishida, T. (2013). The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 172, 38–47. doi: 10.1016/j.jconrel.2013.07.026

Allen, T. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750–763. doi: 10.1038/nrc903

Bae, Y., Jang, W. D., Nishiyama, N., Fukushima, S., and Kataoka, K. (2005). Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst. 1, 242–250. doi: 10.1039/b500266d

Bae, Y., and Kataoka, K. (2009). Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev. 61, 768–784. doi: 10.1016/j.addr.2009.04.016

Biswas, S., Kumari, P., Lakhani, P. M., and Ghosh, B. (2016). Recent advances in polymeric micelles for anti-cancer drug delivery. Eur. J. Pharm. Sci. 83, 184–202. doi: 10.1016/j.ejps.2015.12.031

Blair, H. A., and Deeks, E. D. (2015). Albumin-bound Paclitaxel: a review in non-small cell lung cancer. Drugs 75, 2017–2024. doi: 10.1007/s40265-015-0484-9

Botella, P., and Rivero-Buceta, E. (2017). Safe approaches for camptothecin delivery: structural analogues and nanomedicines. J. Control. Release 247, 28–54. doi: 10.1016/j.jconrel.2016.12.023

Bourgeois-Daigneault, M. C., St-Germain, L. E., Roy, D. G., Pelin, A., Aitken, A. S., Blair, H. A., and Deeks, E. D. (2015). Albumin-bound Paclitaxel: a review in non-small cell lung cancer. Drugs 75, 2017–2024. doi: 10.1007/s40265-015-0484-9

Cheng, Y., and Ji, Y. (2019). RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur. J. Pharm. Sci. 128, 8–17. doi: 10.1016/j.ejps.2018.11.023

Chen, Y., Sun, J., Huang, Y., Lu, B., and Li, S. (2018). Improved cancer immunochemotherapy via optimal co-delivery of chemotherapeutic and immunomodulatory agents. Mol. Pharm. 15, 5162–5173. doi: 10.1021/acs.molpharmaceut.8b00717

Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., et al. (2016). An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun. 7, 13443. doi: 10.1038/ncomms13443

Chen, Y., Zhang, X., Lu, J., Huang, Y., Li, J., and Li, S. (2014). Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. AJPS 16, 600–608. doi: 10.1016/j.s2248-014-9595-6

Cheng, T., Liu, J., Ren, J., Huang, F., Ou, H., Dung, Y., et al. (2016). Green tea catechin-based complex micelles combined with doxorubicin to overcome multidrug resistance. Theranostics 6, 1277–1292. doi: 10.7150/thno.15133

Chitra, M., Sukumar, E., Suja, V., and Devi, C. S. (1994). Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40, 109–113. doi: 10.1159/000239181

Cho, Y. W., Lee, J., Lee, S. C., Huh, K. M., and Park, K. (2004). Hydrotopic agents for study of in vitro paclitaxel release from polymeric micelles. J. Control. Release 97, 249–257. doi: 10.1016/j.jconrel.2004.03.013

Chung, J. E., Tan, S., Gao, S. J., Yongvongsoontorn, N., Kim, S. H., Lee, J. H., et al. (2014). Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. Nat. Nanotechnol. 9, 907–912. doi: 10.1038/nnano.2014.208

Collinot, E. M., Baldes, C., Schaefer, U. F., Edgar, K. I., Wempe, M. F., and Lehr, C. M. (2010). Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm. 7, 642–651. doi: 10.1021/mp900191s

Constantinides, P. M., Han, J., and Davis, S. S. (2006). Advances in the use of nanoparticles and protein drugs for cancer therapy. Adv. Drug Deliv. Rev. 58, 907–916. doi: 10.1016/j.addr.2005.04.016

Chabner, B. A., and Roberts, T. G., Jr. (2005). Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65. doi: 10.1038/nrc1529

Chakravarti, L., Agrawal, R., Dang, S., Gupta, S., and Gabrani, R. (2016). Therapeutic effects of EGCG: a patent review. Expert Opin. Ther. Pat. 26, 907–916. doi: 10.1080/13543776.2016.1203419

Most of these dual-functional micelles rely on passive targeting, so more effective strategies are needed to enhance their targeted delivery, deepen their penetration into the tumor, and enable drug release in response to specific stimuli. Much work remains to be done to translate these promising nanomaterials into the clinic, including scale-up for industrial production and validation studies in appropriate animal models.

AUTHOR CONTRIBUTIONS

YL and JH wrote the manuscript and obtained funding, TZ and QL contributed to the discussion and review of the manuscript.

FUNDING

This work was financially supported by the National Natural Science Foundation of China (81603035 and 81870599), China Postdoctoral Fellowship (2017M612981 and 2018T110986).

Li et al. PEG-Derivatized Dual-Functional Nanomicelles

Frontiers in Pharmacology | www.frontiersin.org 10 July 2019 | Volume 10 | Article 808
1. Introduction

Polymeric micelles are colloid systems formed by the self-assembly of amphiphilic block copolymers in aqueous media. They are composed of a hydrophobic core and a hydrophilic shell, allowing them to encapsulate hydrophobic and hydrophilic drugs in a stable and controlled manner. Various stimuli-responsive materials have been designed for drug delivery and tumor targeting. These micelles can be used to deliver drugs to tumor sites and can be involved in the rational design of drug delivery systems. In this article, we present recent advances in the development of innovative micellar systems as potential drug delivery agents.

2. Design Strategies

A. Angiogenesis Inhibitors

Angiogenesis is the process by which new blood vessels are formed. This process is essential for tumor growth and metastasis. In order to inhibit the angiogenesis of cancer, numerous inhibitors of tumor vessel formation have been developed. The most common angiogenesis inhibitors are the VEGF inhibitors. Treatment of tumors with VEGF inhibitors has been shown to decrease the occurrence of metastasis. It is necessary to develop nanocarrier systems to achieve the selective delivery of VEGF inhibitors to the tumor site. Moreover, the advent of the combination delivery system has already been demonstrated. New strategies have been developed to design polymeric micelles for angiogenesis inhibitors.

B. Anti-Inflammation Agents

Inflammation is an important factor contributing to tumor progression and is usually accompanied by various immune responses. This process is managed by the activation of the immune system. To avoid an inflammatory response, anti-inflammatory strategies can be developed. In order to develop an anti-inflammatory strategy, it is necessary to design micelles that can release anti-inflammatory agents in the tumor microenvironment. Inhibiting inflammation is critical for the effective treatment of cancer.

C. Tumor Biolistic Agents

In recent years, tumor-specific biologic responses have been altered by nanoparticles. In order to develop a biologic response, it is necessary to develop a system that can select and deliver biologic response-related drugs to the tumor site. In addition, the combination therapy of tumor-specific biologic response can be developed. These strategies can be used to develop micelles for tumor biologic agents.

3. Conclusion

Micelles are one of the most widely used drug delivery systems for cancer treatment. In order to develop a micelle delivery system, it is necessary to design a system that can select and deliver target-specific drugs to the tumor site. It is important to develop various strategies to develop micelles for cancer therapy. Moreover, the development of micelle delivery systems for cancer treatment requires the selection and delivery of tumor-specific drugs to the tumor site. In order to develop micelle delivery systems, it is necessary to design a system that can select and deliver tumor-specific drugs to the tumor site. These micelles can be used to deliver drugs to tumor sites and can be involved in the rational design of drug delivery systems.
Zhang, X., Chen, D., Ba, S., Zhu, J., Zhang, J., Hong, W., et al. (2014c). Poly(l-histidine) based triblock copolymers: pH induced reassembly of copolymer micelles and mechanism underlying endo-lysosomal escape for intracellular delivery. Biomacromolecules 15, 4032–4045. doi: 10.1021/bm501075e

Zhang, X., Huang, Y., and Li, S. (2014d). Nanomeric carriers for targeted delivery of anticancer agents. Ther. Deliv. 5, 53–68. doi: 10.1089/tde.13.135

Zhang, X., Huang, Y., Zhao, W., Chen, Y., Zhang, P., Li, J., et al. (2014e). PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel. Mol. Pharm. 11, 2807–2814. doi: 10.1021/mp500181x

Zhang, X., Huang, Y., Zhao, W., Liu, H., Marquez, R., Lu, J., et al. (2014f). Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. Biomacromolecules 15, 4326–4335. doi: 10.1021/bm501339j

Zhang, X., Liu, K., Huang, Y., Xu, J., Li, J., Ma, X., et al. (2014g). Reduction-sensitive dual functional nanomicelles for improved delivery of paclitaxel. Bioconjug. Chem. 25, 1689–1696. doi: 10.1021/bc500292j

Zhang, X., Lu, J., Huang, Y., Zhao, W., Chen, Y., Li, J., et al. (2013). PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug. Chem. 24, 464–472. doi: 10.1021/bc300608h

Zhang, Y., Huang, Y., and Li, S. (2014h). Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 15, 862–871. doi: 10.1208/s12249-014-0113-2

Zhang, X., Huang, Y., Zhao, W., Lu, J., Zhang, P., Zhang, X., et al. (2014i). Fmoc-conjugated PEG-vitamin E micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity. AAPS J. 16, 1282–1291. doi: 10.1088/0961-7.12248-014-9651-2

Zhang, Z., Tan, S., and Feng, S. S. (2012). Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33, 4889–4906. doi: 10.1016/j.biomaterials.2012.03.046

Zhang, D., Liu, N., Shi, K., Wang, X., and Wu, G. (2015). Preparation of a multifunctional verapamil-loaded nano-carrier based on a self-assembling PEGylated prodrug. Colloids Surf. B Biointerfaces 135, 682–688. doi: 10.1016/j.colsurfb.2015.08.018

Zhou, M., Huang, Y., Chen, Y., Xu, J., Li, S., and Guo, X. (2016). PEG-Fmoc-buprofen conjugate as a dual functional nanocarrier for paclitaxel. Bioconjug. Chem. 27, 2198–2205. doi: 10.1021/acs.bioconjchem.6b00415

Zhou, Q., Zhang, L., Yang, T., and Wu, H. (2018a). Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int. J. Nanomed. 13, 2921–2942. doi: 10.2147/IJN.S158696

Zhou, Y., Yu, F., Zhang, Z., Chen, G., Wang, K., Sun, M., et al. (2018b). Cyclomodified PEI for combined VEGF siRNA silencing and CXCR4 inhibition to treat metastatic breast cancer. Biomacromolecules 19, 392–401. doi: 10.1021/acs.biomac.7b01487

Zhu, M. M. T., Dansokoh, A. R., and Nielsen, T. O. (2019). Indoleamine dioxygenase inhibitors: clinical rationale and current development. Curr. Oncol. Rep. 21, 2. doi: 10.1007/s19112-019-0750-1

Zunino, F., and Pratesi, G. (2004). Camptothecins in clinical development. Expert Opin. Investig. Drugs 13, 269–284. doi: 10.1517/13543784.13.3.269

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Li, Zhang, Liu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.